Bristol-Myers Squibb: Francis Cuss, MB BChir, FRCP
 
Leadership
Francis Cuss, M.D., F.R.C.P.
Francis Cuss, MB BChir, FRCP
Executive Vice President,
Chief Scientific Officer, R&D

Francis Cuss has served as Chief Scientific Officer since July 2013, and has been a member of the company’s Leadership Team since 2010.

“We need big ideas to advance treatment options across a variety of diseases, but it's only by turning those ideas into reality – into new therapies – that we can help patients,” said Cuss. “I’m confident that our R&D organization has the talent and resources to unlock the potential of our big ideas and ultimately deliver transformational medicines to patients. That is why I come to work every day.”

Francis is a physician with a background in general and academic medicine and broad experience in both pharmaceutical research and development. He joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery. Francis took over additional responsibility for the discovery and exploratory development of potential new medicines in May 2006, and for all Research functions in 2010.

Prior to joining the company, Francis spent 14 years at Schering-Plough and three years at Glaxo, where his career included leadership roles in discovery, clinical research and medical affairs in the U.S. and Europe. Prior to joining the pharmaceutical industry, he was a practicing physician with a specialization in pulmonary medicine. He has also held several academic appointments, most recently as adjunct associate professor at Jefferson Medical College in Philadelphia, PA.

Francis received his medical training in the United Kingdom. He holds medical degrees from Cambridge University, U.K., and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He has published numerous articles and book chapters on topics of medical interest.

February 2017

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.